“We observed a … 62% drop in cervical cancer deaths over the last decade, likely due to HPV vaccination,” said study senior ...

Cervical cancer deaths have plunged dramatically among women under age 25, and researchers at MUSC Hollings Cancer Center ...

Cervical cancer, considered a “highly preventable” disease, has long been declining in the United States — but it’s now on ...

The statistics are alarming. Every two minutes, a woman dies of cervical cancer in countries where access to public health, ...

In the vibrant streets of Nairobi, a silent health crisis is unfolding, casting a shadow over the lives of gay, bisexual, and ...

Delve into the expanding and diverse field of cancer vaccines with various approaches exploiting the immune system to fight ...

Human papillomavirus (HPV) is a common viral infection typically transmitted through intimate contact, primarily during ...

“Public health problems including weakened healthcare systems, outbreaks of emerging and re-emerging infectious diseases, reluctance to receive vaccines (like the HPV vaccine), the evolving burden of ...

Vaccines MarketThe global vaccines market is on a robust growth trajectory, projected to rise from USD 42.7 billion in 2023 ...

The Phase 2b trial is a double-blind, multi-center, randomized, comparator-controlled study to determine the relative efficacy, safety, and immunogenicity of Vaxart’s oral pill COVID-19 vaccine ...

Deep-pocketed investors have adopted a bearish approach towards Merck & Co MRK, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this ...

Vaccination of 27- to 45-year-olds against HPV is less cost-effective than vaccination of younger persons (aged 9 to 26 years).